RA Medical Systems (NYSE: RMED) is one of 121 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare RA Medical Systems to similar companies based on the strength of its dividends, profitability, earnings, institutional ownership, risk, valuation and analyst recommendations.
Insider and Institutional Ownership
31.9% of RA Medical Systems shares are held by institutional investors. Comparatively, 50.6% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.9% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares RA Medical Systems and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|RA Medical Systems||N/A||N/A||N/A|
|RA Medical Systems Competitors||-30.00%||-41.48%||-13.59%|
This is a breakdown of current ratings for RA Medical Systems and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|RA Medical Systems||0||0||4||0||3.00|
|RA Medical Systems Competitors||806||2811||4987||252||2.53|
RA Medical Systems presently has a consensus price target of $14.75, suggesting a potential upside of 263.30%. As a group, “Surgical & medical instruments” companies have a potential upside of 28.86%. Given RA Medical Systems’ stronger consensus rating and higher probable upside, equities analysts plainly believe RA Medical Systems is more favorable than its peers.
Earnings & Valuation
This table compares RA Medical Systems and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|RA Medical Systems||$6.26 million||-$30.83 million||-1.22|
|RA Medical Systems Competitors||$1.48 billion||$146.48 million||40.42|
RA Medical Systems’ peers have higher revenue and earnings than RA Medical Systems. RA Medical Systems is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
About RA Medical Systems
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.
Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.